Purpose: To examine the association between subretinal drusenoid deposits (SDDs) identified by multimodal retinal imaging and visual function in older eyes with normal macular health or in the earliest phases of age-related macular degeneration (AMD).
S
ubretinal drusenoid deposits (SDDs), the leading histologic correlate for reticular pseudodrusen, are space-filling extracellular lesions distinct from drusen because of their location, differential cholesterol content, and independently conferred risk for age-related macular degeneration (AMD) progression. [1] [2] [3] [4] Recently, we showed with multimodal imaging that SDDs are present in 23% of older adults in normal macular health and 52% of those with early AMD, usually appearing as sparse lesions not forming a distinctive pattern. 5 Furthermore, our prospective study has shown that SDDs' presence in normal eyes doubles their risk for incident early AMD 3 years later. 6 Histology and adaptive optics-assisted imaging show that these lesions exert a stage-specific effect on the photoreceptor structure. 4, 7 A growing body of work has documented that SDDs increase the risk for visual deficits, which has been documented under a wide range of ambient lighting conditions, including scotopic (rod mediated), photopic (cone mediated), and mesopic (both rod and cone mediated) conditions. Impairments have been reported for light sensitivity as assessed by microperimetry, [8] [9] [10] low-luminance visual acuity, 11 delayed rod-mediated dark adaptation, 12, 13 contrast sensitivity, 9 and electrophysiologic implicit times as measured by multifocal electroretinogram. 14, 15 These visual effects could be attributable to direct toxicity of the lesions contacting photoreceptors, increased diffusion distance in the subretinal space, and/or a diffuse dysregulation of retinoid processing, among other processes. All these effects would be superimposed on a transport barrier already present in the subjacent retinal pigment epithelium and Bruch membrane, which could also impair visual function. 16 These studies focused on patients seen in retinal referral clinics where tested cohorts were dominated by patients at intermediate AMD or worse.
A novel question for understanding the significance of SDDs is whether these lesions also accentuate visual functional deficits in normal older eyes and in those in the earliest phases of AMD. Although earlier work documented an association between SDDs and exacerbated visual functional deficits as compared with eyes without SDDs, literature to date has not specifically focused on the impact of SDDs on visual function in normal retinal aging or on very early AMD as defined by gold standard definitions of AMD. Here, we examine the association between SDDs identified by multimodal retinal imaging and several aspects of visual function in a very large sample of older eyes in normal macular health and those with early AMD.
Methods
This study used data from the baseline visit of the Alabama Study on Early Age-Related Macular Degeneration (ALSTAR) study. 17, 18 Eligible persons were 1) aged $60 years; 2) in normal macular health (Grade 1) or in the early stages of AMD (Grades 2-4) in the AREDS 9-step classification system, 19 which is based on 3-field color photographs graded by trained and masked evaluators; and 3) free from other ocular diseases. This study was approved by the Institutional Review Board of the University of Alabama at Birmingham and followed the tenets of the Declaration of Helsinki. Written informed consent was obtained from participants after the nature and purpose of the study were described.
Eyes were examined for the presence of SDDs using color fundus photographs (450 Plus camera; Carl Zeiss Meditec, Dublin, CA), infrared reflectance and 488 nm excitation autofluorescence images, and spectral domain optical coherence tomography (SD-OCT) volumes. Spectral domain optical coherence tomography, infrared, and autofluorescence images were captured on the Spectralis HRA + OCT (Heidelberg Engineering, Heidelberg, Germany). The SDD identification process has been described in detail elsewhere 5 and is summarized here. To assess retinal images for the presence of SDDs in SD-OCT, infrared, and autofluorescence images, we used Heidelberg Eye Explorer (HEYEX version 1.6.4.0 with Spectralis Viewing Module 5.3.2.0; Heidelberg Engineering, Heidelberg, Germany). To assess color fundus photographs, we used OphthaVision (version 3.50; Escalon Medical Corp, Ardmore, PA). Spectral domain optical coherence tomography volumes of macula and optic nerve head (ONH) were included. B-scans of the macula volumes were horizontally oriented and centered over the fovea across an area of 20°· 15°(5.7 · 4.2 mm), as reported by the software. B-scans of the ONH volumes were radially oriented and centered over ONH within a circular area of 20°(5.8 ± 0.1 mm) in diameter. Automatic real-time averaging was set between 8 and 18 for both volumes. Spectral domain optical coherence tomography was graded for the presence of SDDs first, followed by the grading of the 3 en face imaging modalities. Our criteria for SDD at the eye level required identification on $1 en face modality and OCT or on $2 en face modalities in the absence of OCT findings (called strict criteria). 5 Because of the many normal eyes in our study population, our criterion included sparse or solitary lesions not discernable as a pattern, in the context of multimodal imaging.
Visual function measurements were performed for each eye unless otherwise noted below. Best-corrected visual acuity was assessed with the Electronic Visual Acuity tester 20 (JAEB Center, Tampa, FL) under photopic conditions (100 cd/m 2 ) and expressed as the logarithm of the minimum angle resolvable. Lowluminance visual acuity was also assessed using the Electronic Visual Acuity tester with participants viewing letters through a 1.5 log unit neutral density filter, which reduced the background luminance to 3.16 cd/m 2 (mesopic conditions). To determine how much logarithm of the minimum angle resolvable decreased under conditions of the lower light level as compared with the photopic (100 cd/m 2 ) assessment, we defined a decrease in visual acuity under low luminance by the increase in logarithm of the minimum angle resolvable. This measure has been referred to as the "low luminance deficit". 21, 22 Contrast sensitivity was estimated with the Pelli-Robson chart 23 (Precision Vision, La Salle, IL) with a mean luminance of 100 cd/m 2 , the letter-by-letter scoring method, 24 and expressed as logarithm of sensitivity. Light sensitivity in the macula was assessed using the Humphrey Field Analyzer (Carl Zeiss Meditec). The 24-2 Swedish Interactive Thresholding Algorithm (SITA) standard protocol was used following the instrument's recommended testing procedure for a white stimulus on a white background. Macular light sensitivity was defined as the average sensitivity (in decibel) of 16 targets falling within the region 9°x 9°grid centered on the fovea. Rodmediated dark adaptation was measured psychophysically using the AdaptDx (MacuLogix, Hummelstown, PA), using a procedure described in detail previously 17 and summarized here. The procedure began with a photobleach (0.25 milliseconds duration, 58,000 scotopic cd/m 2 second intensity; equivalent 83% bleach). The 4°diameter flash was centered at 5°on the inferior vertical meridian (i.e., superior to the fovea on the retina). The test target for measuring light sensitivity was also placed at this position. Fifteen seconds after bleach offset, threshold measurement for a 2°diameter, 500 nm circular target began and continued at 30-second intervals for 20 minutes. Speed of dark adaptation was characterized by the rod-intercept time, defined as the duration (minutes) required for a sensitivity value of 5.0 · 10 23 scotopic cd/m 2 (3.0 log units of attenuation of the stimulus), which is in the latter half of the second component of rod recovery. 25 A higher value for rod-intercept time indicates slower dark adaptation. Dark adaptation was measured in one eye only because of time constraints in the protocol. The eye with better visual acuity was selected for testing. Dark adaptation data were missing for 79 participants because of fixation instability during testing (n = 78) or equipment technical problems (n = 1).
Statistical Analysis
Age and AMD status were described for the overall sample and compared between those eyes with and without SDDs using generalized estimating equations to account for the within-person correlation that occurs when two eyes from the same person are included. For each visual function, linear regression models using generalized estimating equations were used to compare mean values between those eyes with and without SDDs. Adjusted models accounted for the potentially confounding effects of age. The model was repeated only among those with AMD and among those with normal macular health. P , 0.05 was considered statistically significant.
Results
The sample consisted of 1,202 eyes. Eyes were from a participant sample that was 63.9% women and 96.1% white of non-Hispanic origin. Their average age was 69.4 years and ranged from 60 to 92 years (Table 1) . Those eyes with SDDs were from persons who were older on average by approximately 2 years. Subretinal drusenoid deposits were present in 25.0% (n = 300 of 1,202) of the overall sample judged by the strict criteria, with SDD prevalence being higher in those eyes with early AMD (47.1%) than in those in normal macular health (19.3%). These prevalence values at the eye level differ very slightly from our separately reported prevalence values at the person level for older normal adults and those with early AMD using information from both eyes. 5 Of 300 eyes meeting strict criteria for SDDs' presence, 286 met criteria by OCT and one en face modality, and 14 met criteria with 2 en face modalities only. Of 902 eyes without SDDs, 245 had SDD on OCT that was not seen on an en face modality, and in 657 eyes viewed by OCT, lesions were questionable or nondetectable. Table 2 summarizes the visual function results for the overall sample with respect to SDDs' presence or absence. SDDs' presence was not associated with visual functions evaluated with the exception of dark adaptation. The mean rod-intercept time in the total sample was on average approximately 3 minutes longer in eyes with SDDs as compared with eyes with no SDDs (P = 0.0019; age-adjusted, P = 0.0511). When analyses were restricted to normal eyes only (Table 3) , SDDs were not associated with any visual functions, even dark adaptation. The rod-intercept time was very similar for eyes in normal macular health with and without SDDs (11.6 minutes vs. 11.1 minutes, P = 0.4805; age-adjusted, P = 0.8772). When analyses were restricted to early AMD eyes only, SDDs' presence was not associated with any visual functions evaluated with the exception of slowed dark adaptation (P = 0.0213). Rod-intercept time averaged 16.9 minutes in early AMD eyes with SDDs and 12.7 minutes in eyes without SDDs. This association between rod-intercept time and SDDs was no longer statistically significant after age adjustment (P = 0.2645).
Figures 1 and 2 display representative retinal imaging and dark adaptation results, respectively, for 4 eyes, 2 normal and 2 early AMD, to demonstrate the impact of SDDs on dark adaptation. Figure 1 shows infrared reflectance images and SD-OCT B-scans, one without SDD ( Figure 1A ) and one with SDDs ( Figure  1B) . As is common in older eyes with healthy maculas and in eyes with AMD, 26 the SDDs in Figure 1B are located closer to the ONH than the fovea. These 2 older adults in normal macular health, regardless of their SDD status, have similarly fast time courses of sensitivity recovery, as compared with eyes with early AMD (Figure 2 ). Figure 1 , C and D, shows images of 2 eyes at AREDS Step 2 indicating early AMD. Although both eyes have slow dark adaptation as compared with normal eyes, the eye with SDDs ( Figure 1D ) is dramatically slowed. Even after 20 minutes, the eye with early AMD with SDDs still had exhibited little recovery of sensitivity.
Discussion
Even though 19.3% of the eyes in normal macular health in our sample had SDDs, these eyes were not more likely to have abnormal dark adaptation than eyes without SDDs. Eyes in normal macular health (Grade 1) by the AREDS 9-step grading system do not have moderate or substantial drusen coverage (i.e., they had a drusen area ,125 mm) nor do they have pigmentary abnormalities. We previously showed in a study based on these same eyes that SDD lesions in eyes in normal macular health tend to be single or sparsely distributed, not forming the patterns familiar in eyes with intermediate AMD. 5 Our data suggest that SDDs in this early manifestation, combined with the absence of moderate to substantial drusen coverage and pigmentary abnormalities, may be insufficient to impede the time course of dark adaptation. Rather than engendering dark adaptation delays, the significance of SDDs in eyes with normal macular health for AMD progression may be that they serve as a structural marker for future emergence of early AMD. In fact, recently we showed that SDDs in normal eyes doubles the risk for incident early AMD 3 years later. 6 Slowed dark adaptation may require further pathologic steps beyond the mere appearance of SDDs, such as their expansion and resulting confluence 27,28 plus perturbation of retinal pigment epithelium cell bodies in addition to the apical processes. 29 Within this framework, the presence of SDDs remains an important signature not only as phenotypic entities in patients with AMD currently in normal macular health but potentially as a biomarker for increased risk for future visual decline in patients currently in normal macular health, an issue deserving further investigation. Although the presence of SDDs in early AMD was associated with dramatically slowed dark adaptation (on an average a 4-minute increase in the time that rod photoreceptors needed to recover sensitivity after photopigment bleaching), this association is largely attributable to the fact that SDDs are more likely to be found in older eyes. 5 Dark adaptation slows in the later decades of life even in the absence of AMD. 30 Our finding is a reminder that the biological aging process itself is a powerful platform and the strongest risk factor identified to date for the development of early AMD lesions and their functional manifestation. Our finding that the association between SDDs and dark adaptation is largely attributable to aging in our cohort does not conflict with findings reported by Flamendorf et al, 12 who found an association between SDDs and dark adaptation in AMD independent of age, because of important differences in the two study populations. Flamendorf et al 12 focused on a broad range of AMD disease severity including eyes with intermediate AMD and whose fellow eye could have advanced AMD. In contrast, our AMD eyes were all at early AMD (AREDS Grade 2-4 in the 9-step classification system 19 ) , with only 5% of fellow eyes with intermediate AMD and 0.4% of fellow eyes with advanced disease (geographic atrophy or choroidal neovascularization).
Results from this study are striking in that the many aspects of visual function assessed in this study bore no relationship to SDDs in eyes in normal macular health or early AMD. Visual acuity, contrast sensitivity, and light sensitivity testing were all performed under photopic conditions and thus are cone mediated. Cone density, including that in the fovea, remains remarkably stable during the aging process, 31 and the cone photoreceptor mosaic is well preserved in early and intermediate AMD. 32 From this perspective, it is not surprising that these cone-mediated functional tests were insensitive to SDDs' presence in normal and early AMD eyes. With respect to the null associations between SDD and low-luminance acuity and the lowluminance deficit, these foveal tests are performed under mesopic conditions. Although foveal acuity under mesopic conditions relies on cones, rod photoreceptors also have a role through rod-cone coupling and the operation of surround mechanisms in retinal circuitry. Because the spatial density of macular rods is decreased in aging and AMD, 31, 32 and the topography of SDDs overall corresponds closely to the topography of rods in aging 5 and AMD, 26 one might expect mesopic tests to uncover SDDs-associated deficits. Yet our data show that these tests were insensitive to the presence of SDDs in normal and early AMD eyes. However, mesopic and scotopic testing may be more likely to uncover SDDs-associated visual dysfunction when test targets are positioned in retinal areas where rods are most numerous. Alternatively, a strong association between rod-mediated vision and SDDs may not become manifest till later stages of AMD when photoreceptor health is more severely disturbed. A major strength of our study is that single and sparse lesions (i.e., not in a pattern) were evaluated, in the context of multimodal imaging, and the presence of one lesion by itself did not define SDDs' presence in an eye. By adhering to the SDD nomenclature, we are less dependent on seeing a pattern as might be required for reticular pseudodrusen. There were enough correspondences of en face images with OCTs that we felt secure in our designations for the baseline follow-up visit described herein. Also, absent ultrastructural data on SDDs' precursors, our working pathogenic model for SDD formation allows lesions to arise one at a time, rather than in a pattern, and most plausibly in retinal areas where advanced disease will be found. Other data from the ALSTAR cohort provided support for these decision rules. First was the striking correspondence of SDD lesions with the high density of rod photoreceptors in the perifovea, 5 and encircling the ONH, as similarly described for intermediate AMD. 26 Second was the 2-fold risk for incident AMD in AREDS1 (normal) eyes with SDDs by our criteria in this cohort. 6 Other strengths of this study include a very large study sample of eyes (N = 1,202), many times larger than that in previous work on SDDs and visual function in AMD. [8] [9] [10] [11] [12] [13] [14] [15] The ALSTAR study 17, 33, 34 was specifically designed to focus on the transition from normal macular aging to early AMD, an issue that has been largely unexplored in the literature. Unlike earlier research, this study focused on eyes in normal macular health and those in the earliest phases of AMD; previous studies on SDDs and visual function were either directed at eyes with AMD regardless of disease severity or with intermediate and advanced disease. Previous research has suggested that male gender and cardiovascular disease increase the likelihood of SDDs; 35, 36 however, adjustment for these variables in our study did not change results. A limitation of our analyses is that they are cross-sectional, and thus, we cannot discern the temporal relationship between SDDs and visual dysfunction in early AMD or normal macular health. Our sample of early AMD eyes (N = 244) was much smaller than our sample of eyes in normal macular health (N = 858), although still much larger than other studies on SDDs and visual function in AMD.
In conclusion, in contrast to several reports that SDDs are associated with an exacerbation of visual dysfunction in AMD as compared with eyes with no SDDs, [8] [9] [10] [11] 14, 15 SDDs in eyes in normal macular health do not seem to cause visual disturbances, at least as assessed by the visual function tests administered in this study. Eyes in normal macular health with SDDs versus no SDDs had similar distributions of photopic acuity, mesopic acuity, low-luminance deficit, photopic contrast sensitivity, photopic light sensitivity, and rod-mediated dark adaptation. Visual function was also similar in early AMD eyes with and without SDDs, except that eyes with early AMD having SDDs had delayed dark adaptation; however, this deficit seemed to be largely attributable to the advanced age of SDD eyes as compared with eyes with no SDD. Nevertheless, patients in normal macular health and early AMD who have SDDs warrant observation because of their increased risk for incident early AMD and its progression. 6, [37] [38] [39] [40] Fig. 2. Dark adaptation functions for 4 eyes shown in Figure 1 . The time course of recovery of log light sensitivity after photobleach offset is plotted over time for 20 minutes. The eye in normal macular health with no SDDs (age 60) and the eye in normal macular health with SDDs (age 73) had similar recovery functions, as indicated by their similar rod-intercept times (shown by color-coded arrows on the x-axis). The eye with early AMD with no SDDs (age 79) had slower recovery than the eyes in normal macular health. The eye with early AMD with SDDs (age 78) exhibited little sensitivity recovery even after 20 minutes.
